Last Updated: November 8, 2026

RELA Drug Patent Profile

Name: RELA Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Rela patents expire, and what generic alternatives are available?

Rela is a drug marketed by Schering and Smithkline Beecham and is included in two NDAs.

The generic ingredient in RELA is nabumetone. There are two drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the nabumetone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rela

A generic version of RELA was approved as nabumetone by CHARTWELL RX on February 25^th, 2002.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for RELA?
What are the global sales for RELA?
What is Average Wholesale Price for RELA?

Summary for RELA

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	61
DailyMed Link:	RELA at DailyMed

Drug patent expirations by year for RELA

US Patents and Regulatory Information for RELA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	RELA	carisoprodol	TABLET;ORAL	012155-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Smithkline Beecham	RELAFEN	nabumetone	TABLET;ORAL	019583-001	Dec 24, 1991		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Smithkline Beecham	RELAFEN	nabumetone	TABLET;ORAL	019583-002	Dec 24, 1991		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.